Legend Biotech Corporation (FRA:9LB)
15.30
0.00 (0.00%)
At close: Sep 18, 2026
Legend Biotech Revenue
Legend Biotech had revenue of $387.50M USD in the quarter ending June 30, 2026, with 51.90% growth. This brings the company's revenue in the last twelve months to $1.27B, up 59.54% year-over-year. In the year 2025, Legend Biotech had annual revenue of $1.03B with 64.02% growth.
Revenue (ttm)
$1.27B
Revenue Growth
+59.54%
P/S Ratio
2.67
Revenue / Employee
$397.26K
Employees
3,200
Market Cap
2.98B EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.03B | 401.60M | 64.02% |
| Dec 31, 2024 | 627.30M | 342.20M | 120.03% |
| Dec 31, 2023 | 285.10M | 168.10M | 143.66% |
| Dec 31, 2022 | 117.01M | 48.18M | 70.00% |
| Dec 31, 2021 | 68.83M | -6.17M | -8.23% |
| Dec 31, 2020 | 75.00M | 15.02M | 25.04% |
| Dec 31, 2019 | 59.98M | 10.85M | 22.08% |
| Dec 31, 2018 | 49.13M | 25.54M | 108.24% |
| Dec 31, 2017 | 23.59M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biotest GmbH & Co. KGaA | 648.90M |
| Novogenia AG | 54.30M |
| Paion AG | 14.81M |
| MagForce AG | 1.08M |
| co.don AG | 22.00K |
| Biomark Diagnostics | 17.14K |
| bioXXmed AG | 16.73K |
| 2invest AG | -1.64M |
Legend Biotech News
- 5 days ago - Legend Biotech taps Novartis veteran Zhang as CEO - Reuters
- 5 days ago - Legend Biotech appoints Ingrid Zhang as CEO - TheFly
- 5 days ago - Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer - GlobeNewsWire
- 5 days ago - Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July - WSJ
- 9 days ago - Legend Biotech price target lowered to $74 from $78 at Barclays - TheFly
- 10 days ago - Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting - GlobeNewsWire
- 19 days ago - Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Legend Biotech price target lowered to $24 from $29 at TD Cowen - TheFly